NCT03521973 Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children Status COMPLETED Phase PHASE2
NCT03510481 Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali Status COMPLETED Phase PHASE1
NCT03503058 Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria Status COMPLETED Phase PHASE2
NCT03496454 Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model Status COMPLETED Phase NA
NCT03490162 Safety and Pharmacokinetics Study of DM1157 to Treat Malaria Status TERMINATED Phase PHASE1
NCT03436160 Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds Status COMPLETED Phase EARLY_PHASE1
NCT03432039 Preventing Mental Health Problems After Childhood Severe Malaria Status COMPLETED Phase NA
NCT03420053 Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults Status COMPLETED Phase PHASE1
NCT03341754 Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults Status COMPLETED Phase PHASE1
NCT03334747 Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria. Status COMPLETED Phase PHASE2
NCT03304704 Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali Status COMPLETED Phase N/A
NCT03304691 Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali Status COMPLETED Phase N/A
NCT03281291 Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study. Status COMPLETED Phase N/A
NCT03278808 Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis Status WITHDRAWN Phase PHASE2
NCT03276962 Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Status COMPLETED Phase PHASE2